<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02911844</url>
  </required_header>
  <id_info>
    <org_study_id>824861</org_study_id>
    <nct_id>NCT02911844</nct_id>
  </id_info>
  <brief_title>Estrogen Receptor Antagonist in Patients With Pulmonary Arterial Hypertension</brief_title>
  <acronym>ERA-PAH</acronym>
  <official_title>Estrogen Receptor Antagonist in Patients With Pulmonary Arterial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this clinical trial is to examine the feasibility and effects of
      fulvestrant in post-menopausal women with pulmonary arterial hypertension (PAH). The study
      will evaluate how well the drug is tolerated. The study will evaluate changes in circulating
      hematopoietic progenitor cells, plasma hormone levels, NT-proBNP, and other plasma biomarkers
      after the administration of fulvestrant. Changes in tricuspid annular plane systolic
      excursion, stroke volume index, right ventricular fractional area change, and other echo
      parameters after fulvestrant administration will be evaluated as well as changes in distance
      walked in six minutes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 10, 2017</start_date>
  <completion_date type="Actual">December 5, 2018</completion_date>
  <primary_completion_date type="Actual">December 5, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline of Plasma Estradiol Levels</measure>
    <time_frame>Baseline to 9 weeks</time_frame>
    <description>Plasma estradiol levels are obtained and measured from blood samples collected from each participant.
Difference in change from baseline to 9 weeks in plasma estradiol levels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline of Tricuspid Annular Plane Systolic Excursion (TAPSE)</measure>
    <time_frame>Baseline to 9 weeks</time_frame>
    <description>Measure obtained from echocardiogram completed on participants Difference in change from baseline to 9 weeks in TAPSE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline of Six Minute Walk Distance</measure>
    <time_frame>Baseline to 9 weeks</time_frame>
    <description>Measure obtained from six minute walk test completed by participants Difference in change from baseline to 9 weeks in the six minute walk test distance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline of Plasma NT-proBNP Level</measure>
    <time_frame>Baseline to 9 weeks</time_frame>
    <description>Plasma NT-proBNP levels are obtained and measured from blood samples collected from each participant.
Difference in change from baseline to 9 weeks in plasma NT-proBNP levels</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Fulvestrant</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>500 mg administered intramuscularly (as two 5 mL injections) on days 0, 14, 28 and 56</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <description>Fulvestrant 500 mg administered intramuscularly into the buttocks slowly as two 5 mL injections, one in each buttock, on days 0, 14, 28 and 56. Fulvestrant 250 mg (one 5 mL injection) will be used in patients with Child-Pugh Class B liver disease.</description>
    <arm_group_label>Fulvestrant</arm_group_label>
    <other_name>Faslodex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previous documentation of mean pulmonary artery pressure &gt; 25 mm Hg with a pulmonary
             capillary wedge pressure (or left ventricular end-diastolic pressure) &lt; 16 mm Hg and
             pulmonary vascular resistance &gt; 3 WU at any time before study entry.

          -  Diagnosis of PAH which is idiopathic, heritable, drug- or toxin-induced, or associated
             with connective tissue disease, congenital heart disease, portal hypertension, or HIV
             infection.

          -  Most recent pulmonary function tests with FEV1/FVC &gt;50% AND either a) total lung
             capacity &gt; 70% predicted or b) total lung capacity between 60% and 70% predicted with
             no more than mild interstitial lung disease on computerized tomography scan of the
             chest.

          -  Female, post-menopausal state, defined as:

          -  &gt; 50 years old and a) have not menstruated during the preceding 12 months or b) have
             follicle-stimulating hormone (FSH) levels &gt; 40 IU/L or

          -  &lt; 50 years and FSH &gt; 40 IU/L or

          -  having had a bilateral oophorectomy.

          -  Informed consent.

        Exclusion Criteria:

          -  Age &lt; 18.

          -  Treatment with estrogen or anti-hormone therapy (tamoxifen, anastrozole, etc.)

          -  WHO Class IV functional status.

          -  History of breast cancer.

          -  Clinically significant untreated sleep apnea.

          -  Left-sided valvular disease (more than moderate mitral valve stenosis or insufficiency
             or aortic stenosis or insufficiency), pulmonary artery or valve stenosis, or ejection
             fraction &lt; 45% on echocardiography.

          -  Initiation of PAH therapy (prostacyclin analogues or receptor agonists, endothelin-1
             receptor antagonists, phosphodiesterase-5 inhibitors, soluble guanylate cyclase
             stimulators) within three months of enrollment; the dose must be stable for at least 3
             months prior to Baseline Visit. PAH therapy which is stopped and then restarted or has
             dose changes which are not related to initiation and uptitration will be allowed
             within 3 months prior to the Baseline Visit.

          -  Hormone therapy.

          -  Use of warfarin or other anticoagulant (use of aspirin is permitted).

          -  Platelet count &lt;100,000.

          -  Renal failure (creatinine &gt;/= 2.0).

          -  Child-Pugh Class C cirrhosis.

          -  Current or recent (&lt; 6 months) chronic heavy alcohol consumption.

          -  Current use of another investigational drug (non-FDA approved) for PAH.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven M Kawut, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Kawut SM, Pinder D, Al-Naamani N, McCormick A, Palevsky HI, Fritz J, Smith KA, Mazurek JA, Doyle MF, MacLean MR, DeMichele A, Mankoff DA. Fulvestrant for the Treatment of Pulmonary Arterial Hypertension. Ann Am Thorac Soc. 2019 Nov;16(11):1456-1459. doi: 10.1513/AnnalsATS.201904-328RL.</citation>
    <PMID>31314997</PMID>
  </results_reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>September 19, 2016</study_first_submitted>
  <study_first_submitted_qc>September 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2016</study_first_posted>
  <results_first_submitted>November 18, 2019</results_first_submitted>
  <results_first_submitted_qc>December 6, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 9, 2019</results_first_posted>
  <last_update_submitted>December 6, 2019</last_update_submitted>
  <last_update_submitted_qc>December 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fulvestrant</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 18, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT02911844/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fulvestrant</title>
          <description>500 mg administered intramuscularly (as two 5 mL injections) on days 0, 14, 28 and 56
Fulvestrant: Fulvestrant 500 mg administered intramuscularly into the buttocks slowly as two 5 mL injections, one in each buttock, on days 0, 14, 28 and 56. Fulvestrant 250 mg (one 5 mL injection) will be used in patients with Child-Pugh Class B liver disease.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fulvestrant</title>
          <description>500 mg administered intramuscularly (as two 5 mL injections) on days 0, 14, 28 and 56
Fulvestrant: Fulvestrant 500 mg administered intramuscularly into the buttocks slowly as two 5 mL injections, one in each buttock, on days 0, 14, 28 and 56. Fulvestrant 250 mg (one 5 mL injection) will be used in patients with Child-Pugh Class B liver disease.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" lower_limit="52" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Childs-Pugh Class</title>
          <description>Child-Pugh Class consists of five clinical features and is used to assess the prognosis of chronic liver disease and cirrhosis. There are three distinct classes of increasing severity (A, B and C). Class is determined based on a score that accounts for five factors: total bilirubin level, serum albumin, INR, degree of ascites, and degree of hepatic encephalopathy. Class A is considered the best and indicates mild liver disease, Class B is moderate liver disease, and Class C is severe liver disease.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>A</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>B or C</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>World Health Organization functional class</title>
          <description>Classification based on evaluation of the participant.
Class I: Patients without limitation of physical activity. Ordinary physical activity does not cause undue dyspnea or fatigue, chest pain or near-syncope.
Class II: Patients with slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity causes undue dyspnea or fatigue, chest pain or near-syncope.
Class III: Patients with marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes undue dyspnea or fatigue, chest pain or near-syncope.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Class I</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Class II</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Class III</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline of Plasma Estradiol Levels</title>
        <description>Plasma estradiol levels are obtained and measured from blood samples collected from each participant.
Difference in change from baseline to 9 weeks in plasma estradiol levels</description>
        <time_frame>Baseline to 9 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fulvestrant</title>
            <description>500 mg administered intramuscularly (as two 5 mL injections) on days 0, 14, 28 and 56
Fulvestrant: Fulvestrant 500 mg administered intramuscularly into the buttocks slowly as two 5 mL injections, one in each buttock, on days 0, 14, 28 and 56. Fulvestrant 250 mg (one 5 mL injection) will be used in patients with Child-Pugh Class B liver disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline of Plasma Estradiol Levels</title>
          <description>Plasma estradiol levels are obtained and measured from blood samples collected from each participant.
Difference in change from baseline to 9 weeks in plasma estradiol levels</description>
          <units>pg/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.26" lower_limit="-1.7" upper_limit="-0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline of Tricuspid Annular Plane Systolic Excursion (TAPSE)</title>
        <description>Measure obtained from echocardiogram completed on participants Difference in change from baseline to 9 weeks in TAPSE</description>
        <time_frame>Baseline to 9 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fulvestrant</title>
            <description>500 mg administered intramuscularly (as two 5 mL injections) on days 0, 14, 28 and 56
Fulvestrant: Fulvestrant 500 mg administered intramuscularly into the buttocks slowly as two 5 mL injections, one in each buttock, on days 0, 14, 28 and 56. Fulvestrant 250 mg (one 5 mL injection) will be used in patients with Child-Pugh Class B liver disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline of Tricuspid Annular Plane Systolic Excursion (TAPSE)</title>
          <description>Measure obtained from echocardiogram completed on participants Difference in change from baseline to 9 weeks in TAPSE</description>
          <units>millimeter</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="-3" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline of Six Minute Walk Distance</title>
        <description>Measure obtained from six minute walk test completed by participants Difference in change from baseline to 9 weeks in the six minute walk test distance</description>
        <time_frame>Baseline to 9 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fulvestrant</title>
            <description>500 mg administered intramuscularly (as two 5 mL injections) on days 0, 14, 28 and 56
Fulvestrant: Fulvestrant 500 mg administered intramuscularly into the buttocks slowly as two 5 mL injections, one in each buttock, on days 0, 14, 28 and 56. Fulvestrant 250 mg (one 5 mL injection) will be used in patients with Child-Pugh Class B liver disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline of Six Minute Walk Distance</title>
          <description>Measure obtained from six minute walk test completed by participants Difference in change from baseline to 9 weeks in the six minute walk test distance</description>
          <units>meters</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31" lower_limit="10" upper_limit="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline of Plasma NT-proBNP Level</title>
        <description>Plasma NT-proBNP levels are obtained and measured from blood samples collected from each participant.
Difference in change from baseline to 9 weeks in plasma NT-proBNP levels</description>
        <time_frame>Baseline to 9 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fulvestrant</title>
            <description>500 mg administered intramuscularly (as two 5 mL injections) on days 0, 14, 28 and 56
Fulvestrant: Fulvestrant 500 mg administered intramuscularly into the buttocks slowly as two 5 mL injections, one in each buttock, on days 0, 14, 28 and 56. Fulvestrant 250 mg (one 5 mL injection) will be used in patients with Child-Pugh Class B liver disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline of Plasma NT-proBNP Level</title>
          <description>Plasma NT-proBNP levels are obtained and measured from blood samples collected from each participant.
Difference in change from baseline to 9 weeks in plasma NT-proBNP levels</description>
          <units>pg/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.1" lower_limit="6.7" upper_limit="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Fulvestrant</title>
          <description>500 mg administered intramuscularly (as two 5 mL injections) on days 0, 14, 28 and 56
Fulvestrant: Fulvestrant 500 mg administered intramuscularly into the buttocks slowly as two 5 mL injections, one in each buttock, on days 0, 14, 28 and 56. Fulvestrant 250 mg (one 5 mL injection) will be used in patients with Child-Pugh Class B liver disease.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening hemodynamics</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Increased NT-proBNP level</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Shoulder pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Joint pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Worsened dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small size Open-label and uncontrolled design, making it difficult to directly attribute the findings to the study intervention Short duration of the study may have affected the results</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Steven Kawut</name_or_title>
      <organization>University of Pennsylvania</organization>
      <phone>215-573-0258</phone>
      <email>kawut@upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

